Open AccessBortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis
Author(s) -
Fabiana Gentilini,
Anna Levi,
Federico Verde,
Eleonora Russo,
Robin Foà,
Maria Teresa Petrucci
Publication year - 2012
Publication title -
mediterranean journal of hematology and infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 31
ISSN - 2035-3006
DOI - 10.4084/mjhid.2012.035
Subject(s) - bortezomib , medicine , multiple myeloma , dexamethasone , proteasome inhibitor , cystic fibrosis , oncology , gastroenterology , refractory (planetary science) , bone marrow , surgery , physics , astrobiology
Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow microenvironment. Intravenous Bortezomib with or without dexamethasone, is effective and well tolerated in patients with relapsed/refractory multiple myeloma (MM). Methods: We used Bortezomib without corticosteroids, to avoid the risk of lung infection reactivations due to patient’s Pseudomonas aeruginosa colonization, in a MM patient with Cystic Fibrosis. Four 21-day cycles of Bortezomib were administrated at 1.3 mg/m 2 on days 1,4,8 and 11 with a 10 day rest period. Treatment response and toxicity were evaluated. Results: After four cycles of therapy the patient achieved a very good partial response (VGPR) according to the IMWG response criteria, without clinically significant side effects. Conclusions: Bortezomib can be successfully utilized for the management of this difficult disease situation.